Top

Published in:

01-06-2017 | Brief Report

Aromatase expression in atypical ductal hyperplasia in women

Authors: R. J. Santen, D. C. Radisky, A. Degnim, M. H. Frost, C. M. Vachon, K. Ghosh, F. Guestini, K. M. McNamara, H. Sasano

Published in: Breast Cancer Research and Treatment | Issue 3/2017

Abstract

Purpose

To determine the levels of aromatase in atypical ductal hyperplasia (ADH) lesions, tissue surrounding the ADH, and in dense and non-dense normal breast tissue. We postulated that excess aromatase in breast tissue might, through production of increased estrogen, drive the carcinogenic process. Estrogens and their metabolites are thought to contribute to the development of breast cancer through estrogen receptor-mediated mechanisms and genotoxic effects of estrogen metabolites. ADH is a benign lesion of the breast which is associated with substantially increased risk for subsequent development of breast cancer. After 25 years, approximately 30% of women with ADH develop breast cancer. In women with three or more separate ADH lesions at the same time, 47% will develop breast cancer over that time period. Another important risk factor for breast cancer is the presence of mammographically dense breast tissue.

Methods

We utilized quantitative immunochemical analysis of aromatase in biopsy tissue to test this possibility. Previously published results comparing dense with non-dense breast tissue in normal women (Vachon et al. Breast Cancer Res Treat 125:243–252, 2011) were used for comparisons with ADH. A well-characterized histochemical H-score was employed for quantitative assessment of aromatase in the various tissue studied.

Results

The H-score of aromatase staining was statistically significantly higher (p = 0.003) in the ADH epithelium than surrounding epithelial tissue. In order of H-score from highest to lowest were ADH, issue surrounding ADH, dense normal and non-dense normal breast tissues. The levels of aromatase in a subset of women with ADH who went on to develop breast cancer were not higher than in women who did not.

Conclusions

We suggest from these studies that overexpression of aromatase in breast tissue and its resultant increase in estradiol levels may contribute to the later development of breast cancer in women with ADH.

Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7–30CrossRefPubMed

Ozanne EM, Wittenberg E, Garber JE, Weeks JC (2010) Breast cancer prevention: patient decision making and risk communication in the high risk setting. Breast J 16(1):38–47CrossRefPubMed

Ganz PA, Land SR (2008) Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer. [Review] [34 refs]. Menopause 15(4:Suppl):Suppl-803

Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18):1371–1388CrossRefPubMed

Fisher MD, O’Shaughnessy J (2002) Anastrozole may be superior to tamoxifen as adjuvant treatment for postmenopausal patients with breast cancer. Clin Breast Cancer 4:269–271CrossRef

Tchou J, Hou N, Rademaker A, Jordan VC, Morrow M (2004) Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer 100(9):1800–1806CrossRefPubMed

Visvanathan K, Hurley P, Bantug E et al (2013) Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. [Review][Erratum appears in J Clin Oncol. 2013 Dec 1;31(34):4383]. J Clin Oncol 31(23):2942–2962CrossRefPubMed

Hartmann LC, Degnim AC, Santen RJ, Dupont WD, Ghosh K (2015) Atypical hyperplasia of the breast–risk assessment and management options. N Engl J Med 372(1):78–89CrossRefPubMedPubMedCentral

Hartmann LC, Radisky DC, Frost MH et al (2014) Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. Cancer Prev Res 7(2):211–217CrossRef

10.

Page DL, Dupont WD, Rogers LW, Rados MS (1985) Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 55(11):2698–2708CrossRefPubMed

11.

Degnim AC, Dupont WD, Radisky DC et al (2016) Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women. Cancer 122(19):2971–2978CrossRefPubMedPubMedCentral

12.

Allred DC, Mohsin SK, Fuqua SA (2001) Histological and biological evolution of human premalignant breast disease. Endocr-Relat Cancer 8(1):47–61CrossRefPubMed

13.

Barr FE, Degnim AC, Hartmann LC et al (2011) Estrogen receptor expression in atypical hyperplasia: lack of association with breast cancer. Cancer Prev Res 4(3):435–444CrossRef

14.

Shoker BS, Jarvis C, Clarke RB et al (1999) Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol 155(6):1811–1815CrossRefPubMedPubMedCentral

15.

Shoker BS, Jarvis C, Clarke RB et al (2000) Abnormal regulation of the oestrogen receptor in benign breast lesions. J Clin Pathol 53(10):778–783CrossRefPubMedPubMedCentral

16.

Shoker BS, Jarvis C, Sibson DR, Walker C, Sloane JP (1999) Oestrogen receptor expression in the normal and pre-cancerous breast. J Pathol 188(3):237–244CrossRefPubMed

17.

Santen R, Pinkerton J (2002) Benign breast disorders. In: DeGroot LJ, Jameson JL (eds) Endocrinology. W.B. Saunders Company, Philadelphia, pp 2189–2198

18.

Santen RJ, Mansel R (2005) Benign breast disorders. [Review] [89 refs]. N Engl J Med 353(3):275–285CrossRefPubMed

19.

Yue W, Wang JP, Li Y et al (2010) Effects of estrogen on breast cancer development: role of estrogen receptor independent mechanisms. Int J Cancer 127(8):1748–1757CrossRefPubMedPubMedCentral

20.

Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE (1990) Increased cell division as a cause of human cancer. Cancer Res 50(23):7415–7421PubMed

21.

Jefcoate CR, Liehr JG, Santen RJ et al (2000) Tissue-specific synthesis and oxidative metabolism of estrogens. J Natl Cancer Inst Monogr 27:95–112CrossRef

22.

Lavigne JA, Helzlsouer KJ, Huang HY et al (1997) An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res 57(24):5493–5497PubMed

23.

Yager JD, Liehr JG (1996) Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 36:203–232CrossRefPubMed

24.

Yager JD (2000) Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr 27:67–73CrossRef

25.

Wood LD, Parsons DW, Jones S et al (2007) The genomic landscapes of human breast and colorectal cancers.[see comment]. Science 318(5853):1108–1113CrossRefPubMed

26.

Leary RJ, Lin JC, Cummins J et al (2008) Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci USA 105(42):16224–16229CrossRefPubMedPubMedCentral

27.

O’Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC (1998) Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 90(9):697–703CrossRefPubMed

28.

Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ (1998) Mammographic densities and breast cancer risk. Cancer Epidemiol Biomark Prev 7(12):1133–1144

29.

Boyd NF, Jensen HM, Cooke G, Han HL, Lockwood GA, Miller AB (2000) Mammographic densities and the prevalence and incidence of histological types of benign breast disease. Reference Pathologists of the Canadian National Breast Screening Study. Eur J Cancer Prev 9(1):15–24CrossRefPubMed

30.

Santen RJ, Boyd NF, Chlebowski RT et al (2007) Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. [Review] [95 refs]. Endocr Relat Cancer 14(2):169–187CrossRefPubMed

31.

Vachon CM, Sasano H, Ghosh K et al (2011) Aromatase immunoreactivity is increased in mammographically dense regions of the breast. Breast Cancer Res Treat 125(1):243–252CrossRefPubMed

32.

Page DL, Rogers LW (1992) Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Hum Pathol 23(10):1095–1097CrossRefPubMed

33.

Berg JC, Visscher DW, Vierkant RA et al (2008) Breast cancer risk in women with radial scars in benign breast biopsies. Breast Cancer Res Treat 108(2):167–174CrossRefPubMed

34.

Sasano H, Miki Y, Shibuya R, Suzuki T (2010) Aromatase and in situ estrogen production in DCIS (ductal carcinoma in situ) of human breast. J Steroid Biochem Mol Biol 118(4–5):242–245CrossRefPubMed

35.

Sasano H, Anderson TJ, Silverberg SG et al (2005) The validation of new aromatase monoclonal antibodies for immunohistochemistry—a correlation with biochemical activities in 46 cases of breast cancer. J Steroid Biochem Mol Biol 95(1–5):35–39CrossRefPubMed

36.

Santen RJ, Martel J, Hoagland M et al (1994) Stromal spindle cells contain aromatase in human breast tumors. J Clin Endocrinol Metab 79(2):627–632PubMed

37.

Sasano H, Suzuki T, Nakata T, Moriya T (2006) New development in intracrinology of breast carcinoma. [Review] [54 refs]. Breast Cancer 13(2):129–136CrossRefPubMed

38.

Takagi K, Ishida T, Miki Y et al (2013) Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment. Br J Cancer 109(1):100–108CrossRefPubMedPubMedCentral

39.

Shibuya R, Suzuki T, Miki Y et al (2008) Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast. Endocr Relat Cancer 15(1):113–124CrossRefPubMed

40.

Ritte R, Lukanova A, Tjonneland A et al (2013) Height, age at menarche and risk of hormone receptor-positive and -negative breast cancer: a cohort study. Int J Cancer 132(11):2619–2629CrossRefPubMed

41.

Yue W, Wang JP, Li Y et al (2010) Effects of estrogen on breast cancer development: role of estrogen receptor independent mechanisms. Int J Cancer 127(8):1748–1757CrossRefPubMedPubMedCentral

42.

Santen RJ, Yue W, Heitjan DF (2012) Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy. Cancer Epidemiol Biomark Prev 21(7):1038–1048CrossRef

43.

Dupont WD, Parl FF, Hartmann WH et al (1993) Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 71(4):1258–1265CrossRefPubMed

44.

Dupont WD, Page DL, Parl FF et al (1999) Estrogen replacement therapy in women with a history of proliferative breast disease. Cancer 85(6):1277–1283CrossRefPubMed

45.

Page DL, Dupont WD (1998) Benign breast diseases and premalignant breast disease. Arch Pathol Lab Med 122(12):1048–1050PubMed

Title: Aromatase expression in atypical ductal hyperplasia in women
Authors: R. J. Santen
D. C. Radisky
A. Degnim
M. H. Frost
C. M. Vachon
K. Ghosh
F. Guestini
K. M. McNamara
H. Sasano
Publication date: 01-06-2017
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-017-4184-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2017

Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience

Quality of life in patients with recurrent breast cancer after second breast-conserving therapy in comparison with mastectomy: the German experience

Erratum to: ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling

Failure patterns according to molecular subtype in patients with invasive breast cancer following postoperative adjuvant radiotherapy: long-term outcomes in contemporary clinical practice

Immunoglobulin-like domain 4-mediated ligand-independent dimerization triggers VEGFR-2 activation in HUVECs and VEGFR2-positive breast cancer cells

Background parenchymal enhancement on breast MRI: association with recurrence-free survival in patients with newly diagnosed invasive breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer